Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

HRD Testing Heralds a New Biomarker, but Questions Linger

August 5th 2020

Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.

Entrectinib Approved in Europe for NTRK+ Tumors and ROS1+ NSCLC

August 3rd 2020

The European Commission has approved entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non—small cell lung cancer not previously treated with ROS1 inhibitors.

Genetic Counselor Addresses Common Questions About Testing in Oncology

August 1st 2020

Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types.

Long-Term Consequences for Cancer Detection Loom Amid COVID-19

July 30th 2020

The coronavirus disease 2019 has disrupted the global delivery of coordinated cancer care, resulting in declines in routine screening and referrals that could lead to thousands of excess deaths due to delayed diagnoses, experts warn.

Rare TP53 Mutation Confers Risk of Several Cancers in Ashkenazi Jewish Population

July 28th 2020

A lower-risk TP53 mutation has been linked with a specific kind of Li Fraumeni Syndrome which predisposes individuals to a wide range of cancers, and this newly described variant of p53 is most commonly found in the Ashkenazi Jewish population.

FDA Grants BDTX-189 Fast Track Status to Solid Tumors Harboring Select EGFR, HER2 Mutations

July 28th 2020

The FDA has granted a fast track designation to BDTX-189 for use in adult patients with solid tumors harboring an allosteric HER2 mutation or an EGFR or HER2 exon 20 insertion mutation who had progressed on previous treatment and have no acceptable options available.

ASCO and ACCC Collaborate to Boost Racial/Ethnic Representation in Cancer Treatment Trials

July 27th 2020

A new collaboration between the American Society of Clinical Oncology and the Association of Community Cancer Centers aims to encourage the enrollment of more racially and ethnically diverse patients with cancer onto clinical trials.

TRK Inhibitors Are a Safe, Effective Option in TRK Fusion-Positive Cancers

July 24th 2020

Clinical data shows that the TRK inhibitors entrectinib and larotrectinib induce high response rates with favorable toxicity profiles and central nervous system penetration, and are a viable treatment option for patients with advanced TRK fusion-positive cancers.

USC73 Score Predictive of OS in Uterine Serous Carcinoma

July 23rd 2020

A 73-gene proliferative transcriptomic signature was found to better predict overall survival outcomes and potentially be used to personalize treatment in patients with uterine serous carcinoma.

Dr. Roué on the Next Steps With TG-1701 in MCL

July 20th 2020

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.

Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach

July 17th 2020

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Pyrotinib Yields Promising Efficacy and Tolerability Among HER2-Altered Solid Tumors

July 16th 2020

The investigational TKI pyrotinib demonstrated encouraging antitumor activity and a manageable toxicity profile in patients with heavily pretreated HER2-mutant non–small cell lung cancer, as well as other advanced solid tumors harboring activating HER2 alterations.

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma

July 13th 2020

In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.

Dr. Marshall on the Importance of Molecular Testing in Gastrointestinal Cancers

July 13th 2020

John L. Marshall, MD, discusses the importance of molecular testing in gastrointestinal cancers.

Dr. Pennell on Challenges With NGS in Lung Cancer

July 10th 2020

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

Dr. Halmos on the Importance of Identifying Biomarkers in Advanced NSCLC

July 9th 2020

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Müschen Named Inaugural Director of Center of Molecular and Cellular Oncology at Yale Cancer Center and Yale School of Medicine